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A large number of gene products that are enriched in the striatum have ill-deﬁned functions, although
they may have key roles in age-dependent neurodegenerative diseases affecting the striatum, especially
Huntington disease (HD). In the present study, we focused on Abhd11os, (called ABHD11-AS1 in human)
which is a putative long noncoding RNA (lncRNA) whose expression is enriched in the mouse striatum.
We conﬁrm that despite the presence of 2 small open reading frames (ORFs) in its sequence, Abhd11os is
not translated into a detectable peptide in living cells. We demonstrate that Abhd11os levels are
markedly reduced in different mouse models of HD. We performed in vivo experiments in mice using
lentiviral vectors encoding either Abhd11os or a small hairpin RNA targeting Abhd11os. Results show that
Abhd11os overexpression produces neuroprotection against an N-terminal fragment of mutant hun-
tingtin, whereas Abhd11os knockdown is protoxic. These novel results indicate that the loss lncRNA
Abhd11os likely contribute to striatal vulnerability in HD. Our study emphasizes that lncRNA may play
crucial roles in neurodegenerative diseases.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Comprehensive analysis of the molecular “complexity” of the
adult striatum has shown that many of the gene products pref-
erentially expressed in this brain region have a poorly character-
ized function (Brochier et al., 2008). Among these “striatal” gene
products, a nonnegligible fraction has never been studied experi-
mentally. However, their enrichment in the striatum as compared
with other brain regions, suggests they are involved in the func-
tions of the striatum such as implementation of motor and
cognitive behaviors. It is conceivable that they could also play a
key role in the preferential degeneration of the striatum in alar Imaging Research Center
1 46 54 96 22; fax: 33 1 46 54
uillet).
ontributed to the work.
Inc. This is an open access article unumber of neurologic diseases and, as such, they constitute po-
tential therapeutic targets.
Several disorders (e.g., Huntington disease [HD], Huntington
disease type 2, multiple system atrophy, acute poisoning with
mitochondrial toxins, inherited mitochondrial defects, and so
forth) are primarily associated with striatal degeneration
(Damiano et al., 2010) or secondarily lead to striatal dysfunctions
(Parkinson’s disease, L-dopa-induced dyskinesia, drug addiction,
schizophrenia, among others). HD is a dominantly inherited dis-
order with an onset during adulthood. Symptoms include invol-
untary abnormal movements (chorea, dyskinesia, and dystonia),
frontal cognitive deﬁcits, and psychiatric disturbances (Harper,
1991; Walker, 2007). The disease is fatal approximately 15 years
after the onset of symptoms. There is no effective treatment to
slow the progression of HD. HD is caused by a mutation in the
gene encoding the protein huntingtin (Htt) that consists in a CAG
triplet repeat expansion translated into an abnormal poly-
glutamine (polyQ) tract within the N-terminal region of thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1993). This polyQ expansion produces a gain-of-function that is
toxic to neurons through unclear mechanisms, but it is likely that
many different cellular pathways are implicated (Roze et al., 2008).
One major early event in HD is the alteration of transcription (Cha,
2007; Seredenina and Luthi-Carter, 2012). Other early alterations
include intracellular signaling defects, axonal transport alterations
(Borrell-Pages et al., 2006), deregulated autophagy (Winslow and
Rubinsztein, 2008), defects in brain derived neurotrophic factor
transcription, secretion, and transport (Zuccato and Cattaneo,
2014), perturbation of calcium homeostasis (Cowan and
Raymond, 2006), and mitochondrial defects (Damiano et al., 2010).
Althoughmutant Htt (mHtt) protein is ubiquitously expressed in
the brain, degeneration primarily affects the striatum (Tabrizi et al.,
2013). This particular vulnerability may be conferred by factors that
are enriched in the striatum (Brouillet et al., 2005; Desplats et al.,
2006; Thomas, 2006). So far, only a limited list of gene products
preferentially expressed in the striatum have been found to pro-
mote mHtt toxicity, notably the small GTPase Rhes (Subramaniam
et al., 2009), the dopamine type 2 receptor (Benchoua et al.,
2008; Charvin et al., 2005), and the RGS2 protein (Seredenina
et al., 2011). Alternatively, striatum-enriched neuroprotective fac-
tors may be downregulated during HD pathogenesis. For instance,
A(2A) adenosine receptors, whose expression is early impaired in
HD (Blum et al., 2003), have been shown to be neuroprotective
(Mievis et al., 2011). However, all striatal-speciﬁc gene products
with reduced expression in HD have not an effect against mHtt
(Galvan et al., 2012).
We previously reported that 2010001M06Rik transcript, one of
those we have identiﬁed as striatal “markers”, shows markedly
reduced expression in the striatum of the R6/2 mouse model of HD
(Brochier et al., 2008). It has been annotated as a long intergenic
nonprotein coding RNA (LINC00035) by in silico analysis. It has been
renamed ABHD11-AS1 in human and Abhd11os in mouse (for
abhydrolase domain containing 11, opposite strand). The potential
roles of long noncoding RNA in neurobiological regulatory mecha-
nisms and neurologic and psychiatric diseases have been recently
underlined (Tan et al., 2013; Wu et al., 2013). Thus, we aimed at
exploring the potential role of Abhd11os in HD.
Here, we provide experimental evidence that Abhd11os is
noncoding. We next examined its expression in the striatum of 2
additional mouse models of HD that are characterized by a slow
progressing disease phenotype without major neurodegeneration.
Finally, using lentiviral vectors, we tested whether overexpression
or knock-down of Abhd11os could modify mHtt toxicity in the
mouse striatum. Results indicate that Abhd11os is neuroprotective
against mHtt in vivo.
2. Methods
2.1. Animals
Mice were housed in a temperature-controlled room main-
tained on a 12-hour light and/or dark cycle. Food and water were
available ad libitum. All animal studies were conducted according
to the French regulation (EU Directive 86/609dFrench Act Rural
Code R 214-87 to 131). The animal facility was approved by veter-
inarian inspectors (authorization nA 92-032-02) and complies
with Standards for Humane Care and Use of Laboratory Animals of
the Ofﬁce of Laboratory AnimalWelfare (OLAWdn#A5826-01). All
procedures received approval from the ethical committee. Adult
male C57BL/6J mice (25 g each; Charles River, Saint Germain sur
l’Arbresle, France) were used for lentiviral infections.
For endogenous Abhd11os messenger RNA (mRNA) levels study,
we used the transgenic mouse model of HD generated andmaintained in the FvB inbred background, the BACHD mice, that
express full-length human mHtt from its own regulatory elements
on a 240-kb BAC, which contains the intact 170-kb human htt locus
plus about 20 kb of 50 ﬂanking genomic sequence and 50 kb of 30.
We used 9-month-old male BACHDmice for the study as previously
described (Gray et al., 2008).
We also studied 13-month-old knock-in mice expressing
chimeric mouse and/or human exon 1 containing 140 CAG repeats
inserted in themurineHtt gene (KI140) and their littermate controls.
KI140 colony was maintained by breeding heterozygotes KI140
males and females (Menalled et al., 2003). Mice were N3 (B6) on a
129 Sv  C57BL/6 J background. The resulting different genotypes
mice were used for the study and showed no overt abnormalities.
Genotyping was determined from polymerase chain reaction
(PCR) of tail snips taken at 10e15 days of age for BACHD and KI140
mice.
2.2. Lentiviral vector construction, production, and infection
DNA sequences coding for green ﬂuorescent protein (GFP) and
mouse Abhd11os (2010001M06rik) were cloned into the SIN-W-
PGK lentiviral vector (LV) to generate LV-GFP and LV-Abhd11os,
respectively (de Almeida et al., 2002). An Abhd11os-directed
small hairpin RNA (shRNA) (target sequence: 50 GGGATGAAGC-
CATTGCTAA 30) and a Luciferase-targeted shRNA (target sequence:
50 CGTACGCGGAATACTTCGA 30) were cloned into a bicistronic LV
vector (Drouet et al., 2009), in such a way that the infected cells
expressed the reporter protein GFP. The resulting constructs were
designated as LV-shAbhd11os and LV-shLuc, respectively. The
Abhd11os sequence targeted by the shRNA (GGGATGAAGC-
CATTGCTAA) is located in the second exon of the Abhd11os gene.
From the expressed sequence tag and complementary DNA (cDNA)
sequences available in the public databases, this exon is present in
all splice variants.
The lentiviral vectors expressing a wild-type Htt fragment (LV-
Htt171-18Q), a mHtt fragment (LV-Htt171 82Q) or beta-
galactosidase (LV-LacZ) have been described previously (Diguet
et al., 2009; Faideau et al., 2010). Viral particles were produced as
described elsewhere (Hottinger et al., 2000). The particle content of
the viral batches was determined by enzyme-linked immunosor-
bent assay for the p24 antigen (Gentaur, Paris, France). LV-Htt171
18Q and LV-Htt171-82Q were used at a concentration of 150 ng/
mL of p24, LV-Abhd11os, and LV-LacZ at a concentration of 100 ng/mL
of p24. LV-shAbhd11os and LV-shLuc were used at a concentration
of 100 ng/mL of p24. In experiments performed for PCR analysis, LV-
GFP was mixed with LV-Abhd11os or LV-LacZ at a concentration of
50 ng/mL of p24. After being anesthetized (ketamine and/or xyla-
zine), mice received a total volume of 2 mL of lentiviral suspension
into themouse striatum as previously reported (Faideau et al., 2010;
Galvan et al., 2012), using the following stereotaxic coordinates:
1mm anterior and 2mm lateral to the bregma, at a depth of 2.7mm
from the dura, with the tooth bar set at 0.0 mm.
2.3. Histologic and cytological analyses
2.3.1. Brain processing
After deep anesthesia by intraperitoneal injection of a sodium
pentobarbital solution (50 mg per gram of body weight), mice were
transcardially perfused with 100mL of phosphate buffer containing
4% paraformaldehyde at 8 mL/min. The brains were removed,
postﬁxed overnight in the same solution, then cryoprotected by
immersion in a 30% sucrose solution for 24 hours. Free-ﬂoating 30-
mm-thick serial coronal sections throughout the striatum (i.e., 210-
mm intersection space) were collected using a freezing sliding
microtome (SM2400; Leica Microsystems, Wetzlar, Germany).
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Sections were treated with 0.3% hydrogen peroxide for 1 hour,
washed 3 times in phosphate-buffered saline (PBS), blocked in PBS
containing 4.5% normal goat serum for 1 hour, then incubated over-
night at 4 C in PBS containing 3% normal goat serum, and one of the
following antibodies: rabbit anti-DARPP 32 (Santa Cruz Biotech-
nology, Santa Cruz, CA; 1:1000), mouse anti-NeuN (Millipore, Mol-
sheim, France; 1:200), rabbit anti-Ubiquitin (Wako Chemicals, Neuss,
Germany; 1:1000), or mouse anti-hemagglutinin (HA; Covance,
Princeton, NJ; 1:500). Sections were rinsed 3 times in PBS before in-
cubationwith the appropriate anti-IgG biotinylated antibody (Vector
Laboratories, Burlingame, CA) at a 1:5000 dilution for 1 hour. Staining
was visualized by the addition of avidin-biotinylated peroxidase and
incubation with diaminobenzidine or Peroxidase Substrate Kit (Vec-
tor VIP) (Vector Laboratories) for 1 minute. For NeuN immunostain-
ing, we used the M.O.M. immunodetection kit (Vector Laboratories).
Stained sections were mounted on microscopic slides and cover
slipped using Permount.
2.3.3. Quantitative histologic evaluation
The area of the striatal lesions resulting from LV-Htt171-82Q
infection was delineated manually by identifying the border of the
lesion (loss of DARPP-32 and NeuN immunolabelling). Lesion area
was delineated using a 5 objective. Depending on the antero-
posterior extension of the lesions, 3e8 coronal sections were
analyzed for each mouse. Observation of sections and calculation of
the surface of lesioned area were performed using a Leica DM6000
equippedwithamotorized stage andanautomated imageacquisition
and analysis system (Mercator software, Explora Nova, La Rochelle,
France). The volume of the striatal lesion (V) was determined using
theCavalierimethod (Damianoet al., 2013;Diguet et al., 2009;Galvan
et al., 2012). The number of ubiquitin-positive inclusions was quan-
tiﬁed as previously described (Damiano et al., 2013; Diguet et al.,
2009; Galvan et al., 2012) with the following modiﬁcations: the
intersection distance was 210 mm (i.e., one in every 7 sections was
used), and observations were performed using a 10 objective on an
Axioplan 2 Imagingmicroscope (Carl Zeiss, Le Pecq, France) equipped
with a motorized stage and an automated image acquisition and
analysis system (Mercator software, Explora Nova). With this set-up,
objectswith anapparent cross-sectional area>3mm2 (i.e., diameter>
approximately 1 mm) could be reliably detected.
2.4. Real-time quantitative PCR
Adult mice were deeply anesthetized by intraperitoneal injec-
tion of a sodium pentobarbital solution (50 mg per gram of body
weight) before decapitation. The brains were immediately
removed and positioned in a coronal brain matrix (Ted Pella,
Redding, CA).
For the quantiﬁcation of overexpressed or downregulated Abh-
d11os mRNA levels, mice were infected with a mixture of
LV-Abhd11os and LV-GFP or LV-shAbhd11os (bicistronic for GFP)
alone. Injection of LV-LacZ and LV-shLuc were used as controls for
viral load. The striatal region displaying ﬂuorescence was dissected
out using a circular punch (1.5 mm diameter) from 1-mm-thick
fresh coronal brain sections visualized under a ﬂuorescence
binocular microscope (Leica). Total RNA extraction and real-time
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) were performed as previously described (Drouet et al.,
2009; Galvan et al., 2012), using the following primer sequences
Abhd11os-U GGATTGCCTCGGACCTG and Abhd11os-L
GCACCCGCTCTCGAAC. This pair of primers allows detection of all
Abhd11os splice variants containing the intron.
Similar procedure was used for determination of Abhd11os RNA
levels in BACHDmice and KI140 mice. In this latter case, expressionlevels were normalized to the geometric mean of the mRNAs (DCt)
of 3 housekeeping genes (cyclophilin A [PPIA], hypoxanthine
phosphoribosyltranferase [HPRT1], and beta-actin [ACTB]).
We also performed qRT-PCR to quantify Abhd11 RNA in the
striatum after infectionwith LV-Abhd11os or its control. For this the
following primer sequences Abhd11-U CACATTGGAGCCTTCA-
TAGCAG and Abhd11-L CGCTTCCTTGACAACCGA.
2.5. Biochemical analysis
2.5.1. Cell culture
Human embryonic kidney 293T (HEK293T) cells were grown at
37 C in 5% CO2 in Dulbeco’s modiﬁed Eagle’s medium supple-
mented with 10% bovine calf serum,1% L-glutamine, and antibiotics
(50 units/mL penicillin and 50 mg/mL streptomycin).
HEK293T cells were transfected with recombinant Abhd11os
vectors (coding the putative open reading frame 1 (ORF1) or
ORF2 sequencesdsee Supplementary Fig.1) or equivalent
amount of empty vector, using the calcium phosphate method.
Putative ORF1 and ORF2 were subcloned from Abhd11os cDNA
into pcDNA3 expression vector (PGK promoter). Six nucleotides
were retained 50 to the potential ATG start codon to preserve
the endogenous context of translation initiation. A sequence
coding for HA was introduced immediately 50 to the stop
codon. The resulting constructs have the following sequences
(the putative coding sequence is in capital letters; the sequence
encoding the HA tag is underlined):
ORF1: agagggATGAAGCCATTGCTAAGAAGCGCGCGGTGGAA-
GAGGAGCTGGACTCCTGTCGAGCCAGGCTGCGCACAGTGGAGGCTCA
GCTGCTGGAGGTCCTGCAGGAGAAACGCCTACCCATACGACGTGCCTG
ACTACGCCTCCtga and ORF2: gaagacATGCAGCATATGGTTCGA-
GAGCGGGTGCGGAGTCAGCTGCAGGGAGAGCCCAGAGGCACCCTGGG
AACACACGAGAACACAAGCCCGGGCAGAAGTTCCTGGATTCAACTCTC
CCGGGGTCAGTGGGGGCGACGGTGGGCCTACCCATACGACGTGCCTGA
CTACGCCTCCtga.
Negative controls (ORF1DATG and ORF2DATG) were obtained by
deleting the initial ATG codon and, for ORF2, by mutating the
downstream ATG codon into CTG.
2.5.2. Western blotting
Transfected cultured cells were harvested 48 hours after trans-
fection and lyzed in modiﬁed RIPA buffer: 50 mM Tris pH 8.0,
50 mM NaCl, 1 mM EDTA, 0.5% Triton-X100, 1% NP40, and protease
inhibitor cocktail (Roche). Cell lysates were centrifuged at 13,000g
for 20 minutes at 4 C. Total protein concentration was tested with
BCA kit (Pierce).
Equal amounts of total protein extract were subjected to sodium
dodecyl sulfate poly-acrylamide gel electrophoresis in precast 4%e
12% Bis-tris gel (NuPAGE Novex Bis-tris midi gel, 15wells, Life Tech-
nology) or in precast 4%e20% Bis-glycine gel (Thermo-Fisher) and
transferred to nitrocellulose membranes. Blocked membranes (5%
milk inTBS-0.1%Tween-20)were incubatedwith primary antibodies:
HA (1:3000, mouse, Covance), actin (1:4000, rabbit, Sigma), active
caspase-3 (1:800, mouse, Millipore, AB3623), and washed 3 times
with TBS-0.1% Tween-20 for 10 minutes. Membranes were then
labeled with secondary IgG-HRP antibodies raised against each cor-
responding primary antibody. After 3 washes, the membranes were
incubated with Immun-Star WesternC kit (BioRad) according to the
instructions of the supplier. Peroxidase activity was detected with
camera system Fusion TX7 (Fisher scientiﬁc).
2.6. Statistical analysis
All data were expressed as means  standard error of the
mean (SEM). Unpaired Student t test was used for the
Fig. 1. Downregulated expression of Abhd11os in genetic mouse models of HD.
Expression of Abhd11os was measured by RT-qPCR in 9-month-old BACHD mice (A)
and 13-month-old KI140CAG (B). Controls (CTRL) are age-matched wild-type litter-
mates. Results are presented as mean  standard error of the mean. HET, heterozygous
(140Q/þ); HOM, homozygous (140Q/140Q) knock-in mice carrying an expanded CAG
repeat. *p < 0.05, n ¼ 6 mice per group, unpaired Student t test; **p < 0.001, n ¼ 5 mice
per group, 1-way ANOVA and Bonferroni post hoc. Abbreviations: ANOVA, analysis of
variance; HD, Huntington disease.
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compared, a 1-way analysis of variance with multiple compari-
sons using the post hoc Bonferroni test was carried out using
commercially available software (StatView software, version 5.0,
SAS Institute Inc, USA).
3. Results
3.1. Abhd11os RNA is not translated into a detectable peptide in
living cells
ABHD11-AS1 RNA is an approximately 473-base-long transcript
processed from 4 exons in human. ABHD11-AS1 and its mouse
homolog Abhd1os contain 2 small potential ORFs (ORF1, 105 nu-
cleotides and ORF2, 138 nucleotides in mouse), which are
conserved across mammals. It has been shown that small ORFs can
be translated into functional peptides in vivo (Galindo et al., 2007).
Furthermore, Abhd11os transcript has been detected in the poly-
somal fraction of mouse striatal neurons (Supplementary Table 5 of
Heiman et al., 2008). Thus, the possibility that Abhd11os may be
coding for peptides could not be ruled out.
We therefore experimentally examined whether plasmids
expressing either putative ORFs of Abhd11os (ORF1 or ORF2) tagged
with C-terminal HA could generate a detectable peptide after
transfection in HEK293T cells (Supplementary Fig. 1). As negative
controls, ATG sites of each ORF were deleted (ORF1DATG and
ORF2DATG). The transcripts of ORF1 and ORF2 (with or without
ATG) could be readily detected by RT-qPCR 24 hours after trans-
fection. As expected, Western blot analysis of protein extracts from
cells transfected with ORF1DATG or ORF2DATG did not reveal the
presence of an HA tag peptide (Supplementary Fig. 1). As positive
control, in cells transfected with a plasmid coding the mouse
striatal protein Dclk3 tagged with HA, a band at 90 kDa corre-
sponding to full length mouse Dclk3 could be detected. In contrast,
cell transfected with plasmids coding ORF1 or ORF2 did not reveal
the presence of HA-containing low molecular weight peptides.
Consistent with this, no speciﬁc ﬂuorescent signal was observed in
transfected cells subjected to immunoﬂuorescence detection of the
HA tag. These results support the hypothesis that, even when
overexpressed, Abhd11os RNA does not lead to the production of a
peptide. Thus as predicted, Abhd11os is a noncoding RNA.
3.2. Abhd11os expression is downregulated in HD mouse models
A major reduction in Abhd11os RNA levels was noted in the
striatum of R6/2 mice, which express exon 1 of the human HD gene,
containing 150 CAG repeats (the noncoding RNA Abhd11os was
named 2010001M06rik; Brochier et al., 2008). To check that this
loss of expression was not speciﬁc to the R6/2 model, we asked
whether a similar change could be seen in the BACHD mouse
model, which expresses human full-length mHtt (Gray et al., 2008).
We also characterized Abhd11os RNA levels in a knock-in
(KI140CAG) mouse model of HD (Menalled et al., 2003). A signiﬁ-
cant 33% reduction in Abhd11os RNA level was found in the
striatum of 9-month-old BACHD mice as compared with control
age-matched littermates (Fig. 1A). In heterozygous and homozy-
gous KI140CAG mice, a signiﬁcant approximately 70% reduction
was found at 13 months of age (Fig. 1B) as compared with age-
matched wild-type littermates (Fig. 1B).
3.3. Lentiviral vector approach to modulate Abhd11os expression
in vivo
To study how Abhd11os expression could change the neuro-
toxicity of mHtt in striatal neurons in vivo, we chose to use alentiviral model of HD. In this model, stereotaxic injection of LV
encoding a short fragment of mHtt (LV-Htt171-82Q) produces a
progressive loco-regional cell dysfunction and degeneration char-
acterized by mHtt- and ubiquitin-containing inclusions, loss of
markers linked to neuronal integrity, and astrogliosis within
6 weeks (Damiano et al., 2013; Faideau et al., 2010; Galvan et al.,
2012; Ruiz and Deglon, 2012). This versatile model is particularly
suitable to assess in vivo how mHtt toxicity can be modiﬁed by
different proteins or RNA that can be co-expressed with the mutant
protein using injection of a mixture of lentiviral vectors in the
striatum (for a review Ruiz and Deglon, 2012).
For lentiviral-mediated overexpression of Abhd11os in vivo, we
constructed a lentiviral vector expressing full-length mouse Abh-
d11os (LV-Abhd11os). To assess its efﬁciency, we injected it ste-
reotaxically into the mouse striatum together with a lentiviral
vector expressing GFP (LV-GFP). Six weeks after injection, brains
were collected and the ﬂuorescent region expressing GFP (and thus
Abhd11os) was dissected out for RT-qPCR expression analysis. Re-
sults showed that LV-Abhd11os produced a 1.5-fold increase in
Abhd11os expression compared with control (Fig. 2).
For Abhd11os knock-down, we designed a shRNA targeting
Abhd11os. The efﬁcacy of the shRNAwas ﬁrst tested in transfected
Fig. 2. Efﬁciency of the lentiviral vectors (LV) developed for Abhd11os overexpression
and knock-down. (A) Mice were injected with LV-Abhd11os mixed with LV-GFP in a 4:1
ratio in the right striatum and with a lentiviral vector expressing beta-galactosidase
(LV-LacZ; control) mixed with LV-GFP in the left striatum. A second group of mice
was injected with LV-shAbhd11os-GFP (bicistronic construct also expressing GFP) in
the right striatum and with a lentiviral vector expressing a shRNA directed against
luciferase (LV-shLuc-GFP; control) in the left striatum. Six weeks later, the striatal re-
gions expressing GFP (B) were dissected out from fresh slices using a punch (C) and
analyzed by RT-qPCR (D). Results are expressed relative to controls as mean  standard
error of the mean (n ¼ 5 to 7 mice per group). *p < 0.0001, paired Student t test.
Abbreviations: GFP, green ﬂuorescent protein; shRNA, small hairpin RNA.
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of Abhd11os was reduced by approximately 85% by the shRNA
targeting Abhd11os (Supplementary Fig. 1E). We inserted the
corresponding DNA sequence into a bicistronic lentiviral backboneallowing co-expression with GFP (Drouet et al., 2009). The
resulting lentiviral vector (LV-shAbhd11os) was stereotaxically
injected in the striatum of adult C57Bl/6 mice. Six weeks after the
infection, the brains were collected and fresh coronal slices
encompassing the striatum were prepared. Because LV-
shAbhd11os is bicistronic for the GFP, the transduced region was
visible using a ﬂuorescence binocular microscope and could be
precisely resected and processed for RNA extraction. RT-qPCR
analysis showed that LV-shAbhd11os produced a signiﬁcant 75%
reduction in the expression of endogenous Abhd11os as compared
with control (Fig. 2).
The absence of toxicity of LV-Abhd11os and LV-shAbhd11os was
veriﬁed by histologic evaluation 6weeks after infection. Staining for
NeuN and DARPP32, which are well-known markers of neuronal
integrity in the striatum (de Almeida et al., 2002; Diguet et al.,
2009; Drouet et al., 2009; Faideau et al., 2010; Galvan et al.,
2012), revealed no degeneration in the infected striata (Figs. 3
and 4).
Thus, the LV-Abhd11os and LV-shAbhd11os are not neurotoxic
per se and are effective to modulate Abhd11os expression in the
mouse striatum.3.4. Overexpression of Abhd11os protects against mHtt toxicity
To study the effects of Abhd11os overexpression on mHtt
toxicity, we stereotaxically injected a mixed suspension of LV-
Htt171-82Q and LV-Abhd11os into the mouse striatum. At
6 weeks post infection, LV-Htt171-82Q produced, a loss of NeuN
and DARPP32 labeling in vicinity of the injection site, indicating
overt neurodegeneration (Fig. 3). In separate experiments, we
checked that co-infection with LV-LacZ (control) did not change
the size of the lesion seen using NeuN immunohistochemistry
as compared with LV-Htt171-82Q alone (not shown; mean
 SEM; NeuN, Htt171-82Q [n ¼ 8 mice/group]: 0.440 
0.043 mm3; Htt171-82Q/LacZ [n ¼ 6 mice/group]: 0.526 
0.088 mm3; Student t test, nonsigniﬁcant). Quantitative histo-
logic evaluation using NeuN immunohistochemistry showed
that the striatal lesions produced by a mixture of LV-Htt171-
82Q and LV-Abhd11os were signiﬁcantly smaller than those
produced by LV-Htt171-82Q mixed with LV-LacZ (Fig. 3) (mean
NeuN-depleted volume  SEM; Htt171-82Q/Abhd11os [n ¼ 6
mice/group]: 0.236  0.062 mm3; Htt171-82Q/LacZ [n ¼ 9
mice/group]: 0.573  0.086 mm3; Student t test, p < 0.02]. In
line with this, analysis of striatal degeneration using DARPP32
immunohistochemistry also showed that the overexpression of
Abhd11os reduced the lesions produced by LV-Htt171-82Q
(Fig. 3) (mean DARPP32-depleted volume  SEM; Htt171-82Q/
Abhd11os [n ¼ 11 mice/group]: 0.289  0.046 mm3; Htt171-
82Q/LacZ [n ¼ 11 mice/group]: 0.438  0.048 mm3; Student t
test, p < 0.04).
These results indicate that overexpression of Abhd11os can
reduce the neurotoxicity of Htt171-82Q.
We then assessed the number and size of ubiquitin-positive
nuclear inclusions in mice (Fig. 3) injected with a mixture of LV-
Htt171-82Q and LV-Abhd11os or a mixture of LV-Htt171-82Q and
LV-LacZ. Microscopic quantitative analysis of the sections processed
by anti-ubiquitin-immunohistochemistry showed that over-
expression of LV-Abhd11os changed neither the number of
ubiquitin-containing inclusions (mean inclusion number  SEM;
Htt171-82Q/Abhd11os [n ¼ 8 mice/group]: 10,189  1597; Htt171-
82Q/LacZ [n ¼ 8 mice/group]: 11,141  1330; Student t test, p ¼
0.654) nor their mean sizes (inclusion size, Htt171-82Q/Abhd11os
[n ¼ 8 mice/group]: 13.049  1.266 mm2; Htt171-82Q/LacZ [n ¼ 8
mice/group]: 13.875  1.059 mm2; Student t test, p ¼ 0.624).
Fig. 3. Effect of the overexpression of Abhd11os on the toxicity induced by mHtt. Adult male mice received a bilateral intrastriatal injection of a mixture containing LV-Htt171-82Q
with either LV-LacZ (LacZ, control) or LV-Abhd11os. Six weeks after infection, brains were processed for histologic evaluation using anti-DARPP32, anti-NeuN, and anti-ubiquitin-
immunohistochemistry. Left panel: typical coronal mouse brain sections displaying representative areas with depleted staining. Right panel: histograms representing quantitative
determination of the volume with depleted staining in the striatum. Results are expressed as mean  standard error of the mean (n ¼ 6e11 mice/group). *p < 0.05; **p < 0.02,
unpaired Student t test. Scale bars: NeuN, DARPP32, 100 mm; ubiquitin, 50 mm; and (lower images) 20 mm. Abbreviations: LV, lentiviral vectors; mHtt, mutant huntingtin.
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The effects of Abhd11os knock-down on mHtt toxicity were
studied in the samemousemodel. Co-infectionwith LV-Htt171-82Q
and LV-sh Abhd11os produced NeuN-negative striatal lesions that
were signiﬁcantly larger than those produced by co-infection withLV-Htt171-82Q and control LV-shLuc (Fig. 4) (mean NeuN-depleted
volume  SEM; Htt171-82Q/shAbhd11os [n ¼ 7 mice/group]:
0.541 0.124mm3; Htt171-82Q/shLuc [n¼ 7]: 0.253 0.043 mm3;
Student t test, p < 0.05), indicating that Abhd11os depletion may
enhance mHtt toxicity. However, the volume of DARPP32-depleted
area was similar in mice co-infected with LV-Htt171-82Q and
Fig. 4. Effect of the knock down of Abhd11os on the toxicity induced by mHtt. Adult male mice received a bilateral intrastriatal injection of a mixture containing LV-Htt171-82Q with
either LV-shLuc (control) or LV-shAbhd11os. Six weeks after infection, brains were processed for histologic evaluation using anti-DARPP32, anti-NeuN, and anti-ubiquitin-
immunohistochemistry. Left panel: typical coronal mouse brain sections displaying representative areas with depleted staining. Right panel: histograms representing quantita-
tive determination of the volume with depleted staining in the striatum. Results are expressed as mean  standard error of the mean (n ¼ 7e12 mice/group). *p < 0.05, unpaired
Student t test. Scale bars: NeuN, DARPP32, 100 mm; ubiquitin, 50 mm; and (lower images) 20 mm. Abbreviations: LV, lentiviral vectors; mHtt, mutant huntingtin.
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82Q/shAbhd11os [n ¼ 12 mice/group]: 0.488  0.054 mm3;
Htt171-82Q/LacZ [n¼10mice/group]: 0.4540.046mm3; Student t
test, p ¼ 0.64). The number of ubiquitin-positive nuclear inclusions
in LV-shAbhd11os infected striata compared with control showed a
trend toward reduction although it did not reach statistical signiﬁ-
cance (mean inclusion number  SEM; Htt171-82Q/shAbhd11os
[n ¼ 8 mice/group]: 7861  1283; Htt171-82Q/shLuc [n ¼ 10 mice/
group]: 11,221  1497; Student t test, p ¼ 0.118). The mean size of
inclusions in LV-shAbhd11os infected striata was slightly (18.5%)
but signiﬁcantly smaller as compared with LV-shLuc infected striata
(Fig. 4) (mean inclusion size SEM, Htt171-82Q/shAbhd11os [n¼ 9
mice/group]: 8.661  0.544 mm2; Htt171-82Q/shLuc (n ¼ 10 mice/
group): 10.638  0.630 mm2; Student t test, p < 0.04).
Altogether, these results suggest that Abhd11os exerts a neu-
roprotective effect against the striatal toxicity of mHtt in vivo,
whereas its downregulation exacerbates the toxicity of mHtt.
3.6. Abhd11os does not directly downregulate expression of Abhd11
mRNA
The underlying mechanism of the effect of Abhd11os toward
mHtt toxicity is unknown. Because Abhd11os gene overlaps the
antisense 30UTR region of the Abhd11 gene, we asked whether
Abhd11os could directly regulate Abhd11 mRNA expression
through an antisense-like effect where Abhd11os hybridizing to
Abhd11 mRNA and accelerating its degradation could negatively
regulate Abhd11 expression. We performed qRT-PCR to quantify
Abhd11 RNA in the striatum after infection with LV-Abhd11os or its
control. Results showed that overexpression of Abhd11os produced
a slight increase (þ25) in Abhd11 mRNA expression
(Supplementary Fig. 2). This indicated that Abhd11os did not
directly downregulate Abhd11 mRNA.
4. Discussion
Different systematic studies aimed at providing a comprehensive
viewof themolecular “complexity” of the striatum have shown that
many of the preferential gene products of this brain region have a
totally unknown function. However, their particular presence in the
striatum as compared with other brain region, suggests that they
play a key role in striatal function such as motor behavior and
cognition.Dependingon thedata sets considered andmethodsused,
numbers can vary substantially, but a large number of gene products
show preferential expression in the striatum. Using a SAGE-based
method, we previously identiﬁed 120 gene products whose
expression levels are at least 5 times higher in the striatum than in
other brain regions (Brochier et al., 2008). Among these “striatal”
gene products, a large proportion are poorly characterized (<100
entries in PubMed), especially in terms of neurobiological functions
and/or roles and for a nonnegligible fraction of these gene products,
experiments have never been reported (0 entry in PubMed). In
comparison, well-known speciﬁc striatal gene products, considered
as striatal markers, such as the phosphatase DARPP32 have hun-
dreds of entries in public bibliographic databases.
In the present study, we focused on the newly identiﬁed striatal
marker Abhd11os and found that its expression is signiﬁcantly
reduced in the striatum of 2 mouse models of HD that express full
length Htt with a pathologic expansion (BACHD and KI140CAG),
which is consistent with the major loss of Abhd11os, we previously
found in the R6/2 model (Brochier et al., 2008). We asked whether
experimental modiﬁcation of Abhd11os expression in the mouse
striatum could change the toxicity of mHtt. For this purpose, we
designed lentiviral vectors encoding Abhd11os and a shRNA tar-
geting Abhd11os. Results showed that these vectors were effectivein increasing and reducing Abhd11os expression, respectively. The
level of overexpression was limited (1.5-fold) using our system.
Possibly, this suggests endogenous mechanisms of regulation, as
Abhd11os has a weak basal RNA expression in healthy organisms.
Indeed, using the very same strategy (same lentiviral vector back-
bone and promoter) for overexpression, we were able to express
more strongly other recombinant transcripts such as mitochondrial
complexes subunits and the striatal protein capucin (Damiano et al.,
2013; Galvan et al., 2012).
To test the effects of Abhd11os on mHtt, we used a lentiviral
model of HD in vivo, which is a highly ﬂexible approach for the
targeted overexpression of a disease-causing gene, with rapid and
progressive phenotypes (Ruiz and Deglon, 2012). This HD model
has already been used to test new experimental therapeutics tar-
geting protein misfolding, mitochondrial defects, cell signaling, and
mHtt itself (Damiano et al., 2013; Drouet et al., 2009; Galvan et al.,
2012; Perrin et al., 2007, 2009; review in Ruiz and Deglon, 2012).
Histologic evaluation showed that Abhd11os overexpression,
although limited, produces a signiﬁcant protective effect, reducing
the volume of striatal lesions as seen using 2 different markers of
striatal neuron integrity (NeuN and DARPP32). Conversely, the
downregulation of Abhd11os was found to be protoxic, increasing
the size of the striatal lesions produced by mHtt as seen using the
neuronal marker NeuN. Lesions as seen by DARPP32 were not
increased. The likely explanation for this is that at 6 weeks post-
infection mHtt produced its maximal loss of DARPP32 neurons. In
this model, loss of DARPP32 appears early after infection (de
Almeida et al., 2002) and corresponds to a dysfunction of striatal
neurons at ﬁrst while NeuN immunoreactivity is spared. At later
time points after infection, the loss of DARPP32 achieves its
maximum, whereas NeuN loss which represents actual degenera-
tion is still at its initial stage (Diguet et al., 2009). The number and
size of ubiquitin (positive inclusions in the striatum, a neuropath-
ologic hallmark of HD)were not changed by increased expression of
Abhd11os. The shRNA targeting Abhd11os produced a signiﬁcant
but small (15%) reduction in the number and size of ubiquitin-
positive inclusions. This small reduction might be attributed to
the enhancement of neuronal cell death, leaving alive neurons that
have the lowest levels of mHtt. These data suggest that the neu-
roprotective and/or protoxic effects resulting from the increased
and/or decreased expression of Abhd11os are likely independent
from a direct effect on mHtt expression and/or elimination and
aggregation in neurons.
In parallel to the in vivo rescue experiments, we examined
whether Abhd11os is truly a noncoding RNA (NCBI reference
sequence: NR_026688). Our experiments showed that expression
of the putative ORFs of Abhd11os in HEK293Tcells could not reveal
the existence of translated peptides. This correlates with the in-
formation provided by bioinformatics databases on the Abhd11os
gene. Of course, we cannot rule out the possibility that the HA tag
would be lost during transgene expression by the cells, but it
would then be possible to detect this detached tag by Western
blot, which was not the case. Thus it is highly probable that the
neuroprotective effect of Abhd11os against mHtt is mediated by its
RNA transcript.
Major efforts have beenmade to identify and explore the various
roles of noncoding RNAs. For example, the ENCODE project has
identiﬁed 9600 long noncoding RNAs (lncRNAs) (>200 nt), and
some hints about their localization and roles in the cells have
emerged (Cech and Steitz, 2014; Wu et al., 2013). Current hypoth-
eses about the mechanisms of action of lncRNAs (Vucicevic et al.,
2014) include interactions with proteins to bring along regulatory
functions (Lai et al., 2013); and binding, guidance, and organization
of chromatin domains to coordinate gene activation (Wang et al.,
2011). They have been described to inﬂuence mRNA processing
L. Francelle et al. / Neurobiology of Aging 36 (2015) 1601.e7e1601.e161601.e15and posttranscriptional regulation (Geisler and Coller, 2013) and to
play direct and indirect roles on modulation of epigenetic regula-
tion (Peschansky and Wahlestedt, 2014). The majority of lncRNAs
expressed in the brain are thought to be brain region speciﬁc and
could even be cell-speciﬁc and subcellular compartment-speciﬁc
(ENCODE project). Increasing number of lncRNAs are being identi-
ﬁed as interacting with genes or proteins implicated in neurode-
generative and psychiatric disorders, but only a few lncRNAs have
so far been implicated in HD, as compared with other neurode-
generative diseases (Bhan and Mandal, 2014; Tan et al., 2013; Wu
et al., 2013). Some lncRNAs seem to directly act on mHtt, as
HTTAS_v1 whose overexpression speciﬁcally reduces endogenous
Htt transcript levels (Chung et al., 2011), or DGCR5, a downstream
target of repressor element-1 silencing transcription factor in HD
that exacerbates the toxicity of mHtt (Johnson et al., 2009).
Considering the diverse mechanisms proposed for lncRNA function
(see as reviewfor example (Ulitsky and Bartel 2013), it would be
tempting to think that Abhd11os could produce neuroprotective
effects acting on transcriptional control, for example guiding
chromatin remodeling proteins to target loci or acting with tran-
scriptional factors, where the latter activate transcriptional pro-
gram and Abhd11os could repress previous unstable transcriptional
program. Or, it could also regulate gene expression of the down-
regulated or upregulated genes that are known to be modiﬁed by
mHtt (see as reviews Seredenina and Luthi-Carter, 2012; Zuccato
and Cattaneo, 2014). Abhd11os could also pair with other RNAs to
trigger posttranscriptional regulation known to be altered in HD.
Abhd11os could directly scaffold nuclear or cytoplasmic complexes.
These different mechanisms are essential for the cells to function
properly and may reduce damages induced by mHtt. If Abhd11os is
implicated in some of these functions, its down regulation would
amplify transcriptional dysregulation induced by mHtt, leading to
cell dysfunction and death. As previously said, lincRNAs, as
lncRNAs, are aimed to be brain region speciﬁc, cell-speciﬁc and
subcellular compartment-speciﬁc, and depending on the function
of Abhd11os, the elucidation of the mechanisms underlying the
neuroprotective effects of Abhd11os overexpression against mHtt
toxicity will require further studies. In this respect, it would be
interesting to determine the localization of Abhd11os RNA in sub-
cellular compartments with regard to functions that are most likely
altered by mHtt. In particular, it would be tempting to speculate
that Abhd11os could produce a neuroprotective effect by regulating
the expression of a gene particularly important for neuronal sur-
vival. In line with this, we examined whether Abhd11os could
directly regulate expression of Abhd11 mRNA, because Abhd11os
gene is antisense with the 30UTR region of Abhd11. Our results
showed that overexpression of Abhd11os produces a slight increase
in Abhd11 RNA expression and not a downregulation. In line with
this, bioinformatics search indicates slight downregulation Abhd11
expression in HD mouse models. Thus, Abhd11os does not seem to
directly regulate expression of Abhd11 mRNA levels.
In conclusion, because Abhd11os has a preferential expression in
the striatum and its levels are early reduced in different HDmodels,
it is possible that this downregulation may be involved in the
preferential degeneration of the striatum in HD. Using an in vivo
lentiviral model of HD, we showed that Abhd11os has a neuro-
protective effect against mHtt. It should be emphasized that not all
striatal markers deregulated in HD can modulate the toxicity of N-
terminal fragments of mHtt in this model, and that even fewer
candidates have been found to produce signiﬁcant effects in both
overexpression and downregulation experiments (Galvan et al.,
2012; Ruiz and Deglon, 2012). The present study therefore iden-
tiﬁes a new potential modiﬁer of mHtt toxicity and as such may
help in future works to deﬁne novel therapeutic targets to slow
disease progression.Disclosure statement
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